

CITATION REPORT

List of articles citing

Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β -agonists

DOI: 10.1007/s40258-014-0107-8

Applied Health Economics and Health Policy, 2014, 12, 447-59

Source: <https://exaly.com/paper-pdf/59096567/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 46 | Tiotropium bromide worth it when added to usual asthma care. <i>PharmacoEconomics & Outcomes News</i> , 2014 , 707, 7-7 | 0.1 | |
| 45 | Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. <i>Journal of Asthma and Allergy</i> , 2015 , 8, 1-13 | 3.1 | 27 |
| 44 | Cost-effectiveness of asthma therapy: a comprehensive review. <i>Journal of Asthma</i> , 2015 , 52, 529-37 | 1.9 | 41 |
| 43 | Tiotropium Respimat [®] : A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β -Adrenergic Agonists. <i>Drugs</i> , 2015 , 75, 809-16 | 12.1 | 7 |
| 42 | Utilities for asthma and COPD according to category of severity: a comprehensive literature review. <i>Journal of Medical Economics</i> , 2015 , 18, 550-63 | 2.4 | 16 |
| 41 | Emerging therapeutic options for the treatment of patients with symptomatic asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2015 , 115, 265-271.e5 | 3.2 | 14 |
| 40 | Tiotropium in asthma: what is the evidence and how does it fit in?. <i>World Allergy Organization Journal</i> , 2016 , 9, 29 | 5.2 | 9 |
| 39 | Comment on: "Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β Agonists". <i>Applied Health Economics and Health Policy</i> , 2016 , 14, 117-8 | 3.4 | |
| 38 | Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. <i>European Respiratory Review</i> , 2016 , 25, 54-64 | 9.8 | 28 |
| 37 | Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?. <i>Journal of Asthma</i> , 2017 , 54, 17-23 | 1.9 | 4 |
| 36 | Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. <i>Respiratory Medicine</i> , 2017 , 128, 28-41 | 4.6 | 13 |
| 35 | The evolving role of tiotropium in asthma. <i>Journal of Asthma and Allergy</i> , 2017 , 10, 231-236 | 3.1 | 8 |
| 34 | Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2017 , 9, 386-393 | 5.3 | 17 |
| 33 | Tiotropium in asthma: back to the future of anticholinergic treatment. <i>Clinical and Molecular Allergy</i> , 2017 , 15, 20 | 3.7 | 4 |
| 32 | Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018 , 36, 545-553 | 4.4 | 11 |
| 31 | Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018 , 6, 619-632 | 5.4 | 11 |
| 30 | Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. <i>BioMed Research International</i> , 2018 , 2018, 7473690 | 3 | 7 |

| | | | |
|----|---|----------------|----|
| 29 | Toward effective prescription of inhaled corticosteroids in chronic airway disease. <i>International Journal of COPD</i> , 2018 , 13, 3419-3424 | 3 | 2 |
| 28 | Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives. <i>Canadian Respiratory Journal</i> , 2018 , 2018, 3464960 | 2.1 | 12 |
| 27 | Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. <i>Cost Effectiveness and Resource Allocation</i> , 2018 , 16, 3 | 2.4 | 31 |
| 26 | Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. <i>Pharmacoeconomics</i> , 2018 , 36, 1165-1200 | 4.4 | 15 |
| 25 | Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. <i>Lancet, The</i> , 2019 , 394, 1737-1749 | 4 ⁰ | 73 |
| 24 | A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. <i>Value in Health</i> , 2019 , 22, 1070-1082 | 3.3 | 4 |
| 23 | Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting βagonists in South Korea. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1597-1605 | 2.5 | 3 |
| 22 | Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 423-435 | 2.9 | 3 |
| 21 | Future perspectives of anticholinergics for the treatment of asthma in adults and children. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 473-485 | 2.9 | 10 |
| 20 | Tiotropium in asthma - perspectives for the primary care physician. <i>Postgraduate Medicine</i> , 2021 , 133, 552-564 | 3.7 | 1 |
| 19 | Correlation study between the pharmacokinetics of seven main active ingredients of Mahuang decoction and its pharmacodynamics in asthmatic rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 183, 113144 | 3.5 | 4 |
| 18 | Emerging muscarinic receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 123-130 | 3.7 | 5 |
| 17 | The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. <i>European Respiratory Journal</i> , 2021 , 57, | 13.6 | 1 |
| 16 | Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1939-1947.e7 | 5.4 | 8 |
| 15 | Efficacy and safety of add-on tiotropium in the management of uncontrolled asthma: a patient case series. <i>Journal of Asthma</i> , 2021 , 1-6 | 1.9 | 0 |
| 14 | Cost-utility of tiotropium for children with severe asthma in patients aged 1-5 years. <i>Pediatric Allergy and Immunology</i> , 2021 , 32, 1866-1868 | 4.2 | 4 |
| 13 | The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. <i>Multidisciplinary Respiratory Medicine</i> , 2021 , 16, 787 | 3 | |
| 12 | Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma. <i>Journal of Asthma</i> , 2021 , 1-8 | 1.9 | 5 |

| | | | |
|----|---|-----|---|
| 11 | Developing a novel composite index for monitoring occupational health and wellbeing: A case study in the rail sector in Great Britain. <i>Safety Science</i> , 2021 , 144, 105446 | 5.8 | 0 |
| 10 | A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab in Actual Russian Clinical Practice Data. <i>PediatrĭĭskaĭĭFarmakologiĭ</i> , 2016 , 13, 345-353 | 0.5 | 2 |
| 9 | Pharmacoeconomic analysis of using of tiotropium bromide (Spiriva® Respimat®) as adjunctive therapy in patients with asthma in the Russian Federation. <i>Russian Journal of Allergy</i> , 2015 , 12, 49-58 | 0.2 | |
| 8 | Assessment of second-line treatments for patients with uncontrolled moderate asthma. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 19476-80 | | 7 |
| 7 | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada. <i>ClinicoEconomics and Outcomes Research</i> , 2021 , 13, 957-967 | 1.7 | 1 |
| 6 | Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 398 | 3.5 | 0 |
| 5 | Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. <i>Respiratory Medicine</i> , 2022 , 201, 106934 | 4.6 | |
| 4 | Optimizing asthma management: Role of long-acting muscarinic antagonists. 2022 , | | 2 |
| 3 | Tiotropium for children and adolescents with severe asthma. 1-7 | | 0 |
| 2 | Health-related quality of life in adult patients with asthma according to asthma control and severity: A systematic review and meta-analysis. 13, | | 0 |
| 1 | Clinical characteristics, treatment patterns and adherence in patients with asthma on multiple inhaler triple therapy: a review of findings. 1-8 | | 0 |